search
Back to results

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Primary Purpose

Malignant Solid Tumor

Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
HDM201
Ribociclib
Cabozantinib
Alectinib
Regorafenib
Trametinib
Dabrafenib
Sponsored by
Centre Leon Berard
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malignant Solid Tumor focused on measuring Metastatic Solid Neoplasm, Advanced Solid Tumor, Genomic alteration, Targeted therapy, Cabozantinib, Ribociclib, HDM201, Alectinib, Trametinib, Dabrafenib

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients aged of at least 18 years on day of signing informed consent.
  • Patients with histologically confirmed diagnosis of metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapies or for which standard therapies does not exist or is/are not considered appropriate by the investigator.
  • A multidisciplinary molecular board must have recommended the specific MTT based on the following documented actionable alterations:

    • Cohort HDM201-Ribociclib : amplification of CDK6 and/or CDK4, and/or CDKN2A homozygous deletion, and/or amplification of CCND1 and/or CCND3 with no deletion/losses more than single copy of RB1 by copy number and P53 wild-type.
    • Cohort Cabozantinib : AXL, MET, VEGFR, VEGF, KIT, RET, ROS1, MER, TRKB, FLT3, TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation
    • Cohort Alectinib : Activating ALK alterations: translocation, mutation or amplification
    • Cohort Regoranib : Activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, and/or biallelic inactivation of SMAD4
    • Cohort Trametinib : Activating mutation and/or amplification of KRAS, NRAS, HRAS and/or MAP2K; and/or biallelic inactivation of NF1; and/or activating mutation PTPN11; and/or amplification or translocation of BRAF.
    • Cohort Trametinib + Dabrafenib : BRAF V600 mutation.
  • Previously treated by at least one prior line of treatment in the advanced/metastatic setting.
  • Documented radiological disease progression as per RECIST v1.1 and presence of at least one measurable lesion according to RECIST 1.1 criteria based on screening tumor assessment.
  • Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Adequate organ function
  • Adequate cardiovascular function
  • Specific toxicities related to any prior anti-cancer therapy must have resolved to grade ≤1 , except for alopecia (all grades), grade 2 neuropathy or anemia.
  • Unless infertility is proven, men must agree to use effective contraception
  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days of first dose of study drug and agree to use effective contraception
  • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study procedures as per protocol.
  • Patient must be covered by a medical insurance.

Exclusion Criteria:

  • Patients amenable to therapy with curative intent.
  • Patients participating to another clinical trial with a medicinal product.
  • Patients previously treated with similar MTT meaning any agent targeting the same signaling pathways components.
  • Patients unable to swallow oral medication.
  • Patients with known hypersensitivity to excipients
  • Patients with symptomatic central nervous system (CNS) metastasis who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease.
  • Patients with secondary malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include: basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer, prior malignancy and no evidence of recurrence for ≥ 2 years.
  • Patients using, or requirement to use while on the study, or not respecting the minimal wash-out period of medications
  • Any clinically significant and/or uncontrolled medical disease that could compromise the patient's ability to tolerate study drug or would likely interfere with study procedures or results.
  • Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Patients who are pregnant or breastfeeding women or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through after the last dose of trial treatment (depanding on cohort).

Sites / Locations

  • Institut BergoniéRecruiting
  • Centre Léon BérardRecruiting
  • Institut Paoli CalmettesRecruiting
  • Centre Antoine LACASSAGNERecruiting
  • Institut Curie
  • Institut de Cancérologie de Strasbourg
  • Institut Claudius RegaudRecruiting
  • Institut Gustave RoussyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

HDM201 + Ribociclib

Cabozantinib

Alectinib

Regorafenib

Trametinib

Trametinib + Dabrafenib

Arm Description

Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.

Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.

Patient with ALK alterations: translocation, mutation or amplification

Patient with activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, Platelet Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor 1-2 (FGFR1-2), FLT3 and/or Colony Stimulating Factor 1 Receptor (CSF1R), and/or amplification of the ligands, and/or biallelic inactivation of SMAD4

Patient with activating mutation and/or amplification of KRAS, NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF

Patient with BRAF V600 mutation

Outcomes

Primary Outcome Measures

Progression free rate after 3 months of treatment
The proportion of patients with a complete response (CR), a partial response (PR) or a stable disease (SD) at 3 months.

Secondary Outcome Measures

Objective response rate after 3 months of treatment
The proportion of patients with a complete or a partial response (CR or PR) as best overall response at 3 months.
Duration of Response
Duration of response applies only to patients whose best overall response was a complete response or a partial response (CR or PR). It will be defined as the time from the date of first documented response (CR or PR) to the date of the first documented progression or death due to underlying cancer and censored at the date of the last adequate tumor assessment.
Progression Free Survival
The time from the date of the first study drug administration to the first documented progression according to investigator assessment of RECIST version 1.1 or death due to any cause
Overall survival
The time from the date of the first study drug administration to the date of death due to any cause
Percentage of long-term responders (> 6 months)
The proportion of long term responders (> 6 months)
Adverse Events
Nature, frequency and severity of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

Full Information

First Posted
October 1, 2019
Last Updated
February 9, 2023
Sponsor
Centre Leon Berard
search

1. Study Identification

Unique Protocol Identification Number
NCT04116541
Brief Title
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Acronym
MegaMOST
Official Title
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 28, 2020 (Actual)
Primary Completion Date
February 2026 (Anticipated)
Study Completion Date
November 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Leon Berard

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment. Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion. In this protocol, several MTTs treatment cohorts are planned. This study is designed with the flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts that demonstrate no clinical benefit. Each treatment cohort will be driven separately even though procedures, quality control and reporting, will be common. The protocol will be amended in order to include new treatments or combinations that emerge as being of interest for patients with advanced/metastatic cancers. All eligible patients will receive study drugs as long as patient experiences clinical benefit in the opinion of the investigator, or until unacceptable toxicity, or until symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status, or withdrawal of consent. Patients will be permitted to continue study treatment after progressive disease according to RECIST v1.1 if they meet all of the following criteria and following validation of the Sponsor: Evidence of clinical benefit as assessed by the investigators, Absence of symptoms and signs (including worsening of laboratory values; e.g., new or worsening hypercalcemia) that indicate unequivocal progression of disease, No decline in ECOG Performance Status (PS) that can be attributed to disease progression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Solid Tumor
Keywords
Metastatic Solid Neoplasm, Advanced Solid Tumor, Genomic alteration, Targeted therapy, Cabozantinib, Ribociclib, HDM201, Alectinib, Trametinib, Dabrafenib

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
425 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HDM201 + Ribociclib
Arm Type
Experimental
Arm Description
Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
Arm Title
Cabozantinib
Arm Type
Experimental
Arm Description
Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.
Arm Title
Alectinib
Arm Type
Experimental
Arm Description
Patient with ALK alterations: translocation, mutation or amplification
Arm Title
Regorafenib
Arm Type
Experimental
Arm Description
Patient with activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, Platelet Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor 1-2 (FGFR1-2), FLT3 and/or Colony Stimulating Factor 1 Receptor (CSF1R), and/or amplification of the ligands, and/or biallelic inactivation of SMAD4
Arm Title
Trametinib
Arm Type
Experimental
Arm Description
Patient with activating mutation and/or amplification of KRAS, NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF
Arm Title
Trametinib + Dabrafenib
Arm Type
Experimental
Arm Description
Patient with BRAF V600 mutation
Intervention Type
Drug
Intervention Name(s)
HDM201
Intervention Description
HDM201 120mg, Every 3 weeks, Per os
Intervention Type
Drug
Intervention Name(s)
Ribociclib
Intervention Description
Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
Intervention Type
Drug
Intervention Name(s)
Cabozantinib
Intervention Description
Cabozantinib, 60 mg /day, continuous, Per os
Intervention Type
Drug
Intervention Name(s)
Alectinib
Intervention Description
Alectinib, 600mg twice daily, Per os
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Intervention Description
Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
Intervention Type
Drug
Intervention Name(s)
Trametinib
Intervention Description
Trametinib 2 mg/day, continuous, Per os
Intervention Type
Drug
Intervention Name(s)
Dabrafenib
Intervention Description
Dabrafenib 150 mg twice daily, Per os
Primary Outcome Measure Information:
Title
Progression free rate after 3 months of treatment
Description
The proportion of patients with a complete response (CR), a partial response (PR) or a stable disease (SD) at 3 months.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Objective response rate after 3 months of treatment
Description
The proportion of patients with a complete or a partial response (CR or PR) as best overall response at 3 months.
Time Frame
3 months
Title
Duration of Response
Description
Duration of response applies only to patients whose best overall response was a complete response or a partial response (CR or PR). It will be defined as the time from the date of first documented response (CR or PR) to the date of the first documented progression or death due to underlying cancer and censored at the date of the last adequate tumor assessment.
Time Frame
Up to 3 years
Title
Progression Free Survival
Description
The time from the date of the first study drug administration to the first documented progression according to investigator assessment of RECIST version 1.1 or death due to any cause
Time Frame
Up to 3 years
Title
Overall survival
Description
The time from the date of the first study drug administration to the date of death due to any cause
Time Frame
Up to 3 years
Title
Percentage of long-term responders (> 6 months)
Description
The proportion of long term responders (> 6 months)
Time Frame
6 months
Title
Adverse Events
Description
Nature, frequency and severity of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time Frame
Up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients aged of at least 18 years on day of signing informed consent. Patients with histologically confirmed diagnosis of metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapies or for which standard therapies does not exist or is/are not considered appropriate by the investigator. A multidisciplinary molecular board must have recommended the specific MTT based on the following documented actionable alterations: Cohort HDM201-Ribociclib : amplification of CDK6 and/or CDK4, and/or CDKN2A homozygous deletion, and/or amplification of CCND1 and/or CCND3 with no deletion/losses more than single copy of RB1 by copy number and P53 wild-type. Cohort Cabozantinib : AXL, MET, VEGFR, VEGF, KIT, RET, ROS1, MER, TRKB, FLT3, TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation Cohort Alectinib : Activating ALK alterations: translocation, mutation or amplification Cohort Regoranib : Activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1, and/or amplification of the ligands, and/or biallelic inactivation of SMAD4 Cohort Trametinib : Activating mutation and/or amplification of KRAS, NRAS, HRAS and/or MAP2K; and/or biallelic inactivation of NF1; and/or activating mutation PTPN11; and/or amplification or translocation of BRAF. Cohort Trametinib + Dabrafenib : BRAF V600 mutation. Previously treated by at least one prior line of treatment in the advanced/metastatic setting. Documented radiological disease progression as per RECIST v1.1 and presence of at least one measurable lesion according to RECIST 1.1 criteria based on screening tumor assessment. Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. Adequate organ function Adequate cardiovascular function Specific toxicities related to any prior anti-cancer therapy must have resolved to grade ≤1 , except for alopecia (all grades), grade 2 neuropathy or anemia. Unless infertility is proven, men must agree to use effective contraception Women of child-bearing potential must have a negative serum pregnancy test within 7 days of first dose of study drug and agree to use effective contraception Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study procedures as per protocol. Patient must be covered by a medical insurance. Exclusion Criteria: Patients amenable to therapy with curative intent. Patients participating to another clinical trial with a medicinal product. Patients previously treated with similar MTT meaning any agent targeting the same signaling pathways components. Patients unable to swallow oral medication. Patients with known hypersensitivity to excipients Patients with symptomatic central nervous system (CNS) metastasis who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients with secondary malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include: basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer, prior malignancy and no evidence of recurrence for ≥ 2 years. Patients using, or requirement to use while on the study, or not respecting the minimal wash-out period of medications Any clinically significant and/or uncontrolled medical disease that could compromise the patient's ability to tolerate study drug or would likely interfere with study procedures or results. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Patients who are pregnant or breastfeeding women or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through after the last dose of trial treatment (depanding on cohort).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Yves BLAY, MD
Phone
+33478785126
Email
jean-yves.blay@lyon.unicancer.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Olivier TREDAN, MD
Phone
+33478782828
Email
olivier.tredan@lyon.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Yves BLAY, MD
Organizational Affiliation
Centre Leon Berard
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut Bergonié
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antoine ITALIANO, PHD
Phone
05 56 33 32 44
Email
a.italiano@bordeaux.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Kevin BOURCIER
First Name & Middle Initial & Last Name & Degree
Sophie COUSIN
First Name & Middle Initial & Last Name & Degree
Thomas GRELLETY
First Name & Middle Initial & Last Name & Degree
Simon PERNOT
First Name & Middle Initial & Last Name & Degree
Camille MAZZA
First Name & Middle Initial & Last Name & Degree
Diego TEYSSONNEAU
First Name & Middle Initial & Last Name & Degree
Maud TOULMONDE
Facility Name
Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Yves BLAY, MD
Phone
04 78 78 27 57
Email
jean-yves.blay@lyon.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Jean-Yves BLAY, MD
First Name & Middle Initial & Last Name & Degree
Philippe CASSIER, MD
First Name & Middle Initial & Last Name & Degree
Olivier TREDAN, MD
Facility Name
Institut Paoli Calmettes
City
Marseille
ZIP/Postal Code
13273
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François BERTUCCI, MD
Phone
04 91 22 35 37
Email
bertuccif@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Anthony GONCALVES, MD
Phone
04 91 22 37 89
Email
goncalvesa@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
François BERTUCCI, MD
First Name & Middle Initial & Last Name & Degree
Anthony GONCALVES, MD
Facility Name
Centre Antoine LACASSAGNE
City
Nice
ZIP/Postal Code
06189
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Esma SAADA-BOUZID, MD
Phone
04 92 03 15 14
Email
esma.saada-bouzid@nice.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Esma SAADA-BOUZID, MD
First Name & Middle Initial & Last Name & Degree
Agnès DUCOULOMBIER
First Name & Middle Initial & Last Name & Degree
Joël GUIGAY
First Name & Middle Initial & Last Name & Degree
Nicolas MARTIN
First Name & Middle Initial & Last Name & Degree
Magalie Pascale TARDY
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75248
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe LE TOURNEAU, MD
Phone
01 44 32 46 75
Email
christophe.letourneau@curie.fr
First Name & Middle Initial & Last Name & Degree
Delphine LOIRAT, MD
Phone
01 44 32 46 75
Email
delphine.loirat@curie.fr
First Name & Middle Initial & Last Name & Degree
Christophe LE TOURNEAU, MD
First Name & Middle Initial & Last Name & Degree
Delphine LOIRAT, MD
First Name & Middle Initial & Last Name & Degree
Marie-Paule SABLIN, MD
Facility Name
Institut de Cancérologie de Strasbourg
City
Strasbourg
ZIP/Postal Code
67033
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauriane EBERST, MD
Phone
0368767168
Email
l.eberst@icans.eu
First Name & Middle Initial & Last Name & Degree
Philippe BARTHELEMY, MD
First Name & Middle Initial & Last Name & Degree
Christine BELLETIER, MD
First Name & Middle Initial & Last Name & Degree
Meher BEN ABDELGHANI, MD
First Name & Middle Initial & Last Name & Degree
Mickael BURGY, MD
First Name & Middle Initial & Last Name & Degree
Pascale CHIAPPA, MD
First Name & Middle Initial & Last Name & Degree
Justine GANTZER, MD
First Name & Middle Initial & Last Name & Degree
Sophie MARTIN, MD
First Name & Middle Initial & Last Name & Degree
Roland SCHOTT, MD
First Name & Middle Initial & Last Name & Degree
Philippe TRENSZ, MD
Facility Name
Institut Claudius Regaud
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlos-Alberto GOMEZ-ROCA, MD
Phone
05 31 15 51 01
Email
gomez-roca.carlos@iuct-oncopole.fr
First Name & Middle Initial & Last Name & Degree
Jean-Pierre DELORD, MD
Phone
05 31 15 51 01
Email
delord.jean-pierre@iuct-oncopole.fr
First Name & Middle Initial & Last Name & Degree
Carlos-Alberto GOMEZ-ROCA, MD
First Name & Middle Initial & Last Name & Degree
Jean-Pierre DELORD, MD
First Name & Middle Initial & Last Name & Degree
Iphigénie KORAKIS, MD
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Axel LE CESNE, PhD
Phone
01 42 11 43 16
Email
axel.lecesne@gustaveroussy.fr
First Name & Middle Initial & Last Name & Degree
Rastislav BAHLEDA, MD
First Name & Middle Initial & Last Name & Degree
Benjamin VERRET, MD

12. IPD Sharing Statement

Learn more about this trial

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

We'll reach out to this number within 24 hrs